PSYCH VIRTUAL INVESTOR SUMMIT: EUROPE & ASIA – HAPPENING LIVE NOW!

Our first PSYCH Virtual Investor Summit: Europe & Asia is officially underway – but it isn’t too late to join in. Simply register for complimentary tickets, and join us as we engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors.

Featured speakers include Ronan Levy, Co-Founder & Executive Chairman, Field Trip Health Ltd.; Peter Reitano, Chief Executive Officer, Gwella; Anthony Tennyson, Chief Executive Officer, Awakn Life Sciences; Nick Murray, Chief Executive Officer, Wake Network; and keynote speaker, Professor David Nutt, Director of Neuropsychopharmacology, Imperial College London and Head of Research, Awakn Life Sciences.

Today’s event runs from 12:00 to 18:00 BST / 07:00 to 13:00 EST. Check out the schedule for full details. Hope to see you there.

RICK DOBLIN: ON 35 YEARS OF MAPS, OPPORTUNITIES FOR PSYCHEDELIC INVESTORS AND THE PATH TO CREATING A STRONG INDUSTRY

This month, the Multidisciplinary Association of Psychedelic Studies (MAPS) celebrated a milestone: 35 years of research and advocacy of psychedelics.

Founded in 1986, the US-based non-profit research and educational organisation has worked to develop medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics.

Founder Rick Doblin sat down with PSYCH to highlight the group’s successes and challenges of the last 35 years and to take a deep dive into the present and future of psychedelic business and its path to profitability, including:

  • Drug policy reform and its impact on psychedelic business

  • The usefulness and morality of psychedelic patents vs. data exclusivity

  • The promise of emerging shorter-acting psychedelics & market hype

  • The challenge of retaining talented staff at a psychedelic non-profit and the value of non-profits to big business

  • Keys to shifting cultural attitudes around psychedelics & ensuring the healthcare supply chain can meet demand

  • The path to profitability in psychedelics, the timeline for medical clearance and licensed legalisation

View the entire interview on our website and subscribe to the new PSYCH Youtube channel to stay up-to-date on all the latest PSYCH conversations.

BUSINESS & INVESTMENT


Peter Thiel-backed psychedelics start-up plans to raise US$100 million in IPO.


Silo Wellness announces licensing agreement of psilocybin nasal spray in Colombia and Brazil.


MINDCURE claims new AI platform will lead to big improvements in psychedelic-driven mental healthcare treatments.


PharmaTher close to finalising development of psychedelic product programmes.


Core One Labs signs letter of intent to acquire psychedelic-based pharmaceuticals developer Akome.


Push to decriminalise psychedelics in California could benefit Creso Pharma.


Investors are optimistic about opportunities in psychedelic-inspired medicines.


Cybin appoints renowned physicians to advisory board overseeing clinical psychedelic therapeutics trials.


Launch of online community for people interested in legally exploring or offering psychedelic-assisted therapy launches.


Tryp Therapeutics reports on key milestones for 2021 including advancement of drug delivery platforms.


Silo Wellness appoints Phytomedicine business leader as board member.


Awakn Life Sciences announces two key appointments to its board of directors.


Attorney specialising in drug investments and regulation thinks magic mushrooms could be next big opportunity.


PharmaTher applies for second phase clinical trial evaluating ketamine in the treatment of Parkinson’s disease.


Delic CEO discusses building a legal psychedelic ecosystem.


Cryptocurrencies could be a huge boon for psychedelics.


Mindset Pharma announces additional gross proceeds of over US$1 million.


Creso Pharma signs agreements with nanotechnology company to further progress research into hallucinogenic mushrooms.


Lobe Sciences appoints Yale University psychiatrist to scientific advisory board to develop psychedelic therapies.


Nova announces data bank to support development of psilocybin-based compounds in the diagnosis and treatment of autism.


Mindset Pharma confirms proof-of-concept across its entire new drug programme portfolio.


Cluny Capital completes qualifying transaction and changes name to ‘The Good Shroom Company’.

RESEARCH & SCIENCE


Psychedelics are transforming the way we understand depression and its treatment.


Inside the UK experiment that could bring psychedelic drugs to the NHS.


Beckley Psytech partners with Fluence to create psychedelic therapy training programme.


Psychedelics re-emerging in Canada as treatment for mental health conditions such as anxiety and depression.


University of California launches psychedelics division with US$6.4 million private funding.


LSD is poised for a comeback in Canada as treatment for substance abuse and mental health conditions.


This is what happens to your brain when you take hallucinogenic drugs.


New poll suggests users consider psilocybin the safest recreational drug.

REGULATION & LEGISLATION


California bill to legalise possession of psychedelics clears second senate committee.


More US governors announce support for legislation that would expand research into psychedelic medicine.